Clinical Trial Update: Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC. [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial for locally advanced, MSS/pMMR rectal cancer evaluating radiotherapy with iparomlimab and tuvonralimab (QL1706), plus regorafenib and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Regorafenib (regorafenib)
• Tuvonralimab (QL1706)
• iparomlimab

Snippet

Sponsor: Sun Yat-sen University | Conditions: Rectal Cancer Patients | Phase 2 | Status: RECRUITING